Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line

Journal of Controlled Release

Volumn 59, Issue 2, 1999, Pages 133-148

  Minko, Tamara ^a   Kopečková, Pavla ^a,b   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Adriamycin; Doxorubicin; Gene expression; HPMA copolymer; Metabolism; Multidrug resistance; Ovarian carcinoma

Indexed keywords

COPOLYMER; DOXORUBICIN; NONOXINOL 9; PACLITAXEL; POLYMETHACRYLIC ACID DERIVATIVE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM EXPOSURE; MULTIDRUG RESISTANCE; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL LINE;

CELL DIVISION; DNA, COMPLEMENTARY; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION; GENES, MDR; GLUCOSE; HUMANS; METHACRYLATES; MITOCHONDRIA; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; PACLITAXEL; POLYMERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0344142519     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(98)00186-2     Document Type: Article

References (43)

1. Kool M., de Haasde M., Scheffer G.L., Schapper R.J., van Eijk J.T., Juijn J.A. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
2. German U.A. P-glycoprotein: a mediator of multidrug resistance in tumour cells. Eur. J. Cancer. 32A:1996;927-944.
3. Loe D.W., Deeley R.G., Cole S.P.C. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer. 32A:1996;945-957.
4. Breuninger L.M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S.A., Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 55:1995;5342-5347.
5. Wei L.-Y., Roepe P.D. Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry. 33:1994;7229-7238.
6. Kruh G.D., Chan A., Myers K., Gaughan K., Miki T., Aaronson S.A. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res. 54:1994;1649-1652.
7. Krishnamachary N., Center M.S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:1993;3658-3661.
8. Campling B.G., Young L.C., Baer K.A., Lam Y.-M., Deeley R.G., Cole S.P.C., Gerlach J.H. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin. Cancer Res. 3:1997;115-122.
9. Murray G.I., Taylor V.E., McKay J.A., Weaver R.J., Ewen S.W., Melvin W.T., Burke M.D. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J. Pathol. 177:1995;147-152.
10. Hamaguchi K., Godwin A.K., Yakushiji M., O'Dwyer P.J., Ozols R.F., Hamilton T.C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53:1993;5225-5232.
11. Hayes J.D., Pulfold D.J. The glutathione S-transferase supergene family: regulation of GST and contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:1995;445-600.
12. Kerbel R.S. A cancer therapy resistant to resistance. Nature. 390:1997;335-336.
13. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
14. Minko T., Kopečková P., Pozharov V., Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release. 54:1998;223-233.
15. T. Minko, P. Kopečková, V. Pozharov, J. Kopeček, Peculiarities of apoptosis induction and cell metabolism in human ovarian carcinoma cell lines exposed to free and HPMA copolymer bound adriamycin, in: Proceedings of the 25th International Symposium on the Controlled Release of Bioactive Material, Las Vegas, NV, 22-24 June 1998, pp. 99-100.
16. Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53:1993;4238-4242.
17. Suzuki S., Inoue K., Hongoh A., Hashimoto Y., Yamazoe Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukemia cell by an immunoliposome targeting transferring receptor. Br. J. Cancer. 76:1997;83-89.
18. de Verdiere A.C., Dubernet C., Némati F., Soma E., Appel M., Ferté J., Bernard C., Puisieux F., Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer. 76:1997;198-205.
19. Omelyanenko V., Gentry C., Kopečková P., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 2. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer. 75:1998;600-608.
20. Omelyanenko V., Kopečková P., Gentry C., Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release. 53:1998;25-37.
21. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs, U.S. Pat. 5,037,883 (Aug. 6, 1991).
22. Omelyanenko V.G., Kopečková P., Gentry C., Shiah J.-G., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the methods of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Targeting. 3:1996;357-373.
23. Rejmanová P., Labský J., Kopeček J. Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids. Makromol. Chem. 178:1977;2159-2168.
24. Spoelstra E.C., Dekker H., Schuurhuis G.J., Broxterman H.J., Lankelman J.P. Glycoprotein drug efflux pump involved in the mechanism of intrinsic drug resistance in various colon cancer cell lines. Biochem. Pharmacol. 41:1991;349-359.
25. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growing/cell kill. J. Immunol. Methods. 119:1989;203-210.
26. K.D.C. Stoodley, T. Lewis, C.L.S. Stainton, Applied Statistical Techniques, Ellis Horwood, Chichester, 1980.
27. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods. 89:1986;271-277.
28. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Wunder J.S., Andrulis I.L., Gazdar A.F., Willman C.L., Griffith B., Von Hoff D.D., Roninson I.B. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 87:1990;7160-7164.
29. van Hille B., Lohri A., Reuter J., Herrmann R. Assessment of drug-induced dysregulations among seven resistance-associated genes in human tumor cell lines. Anticancer Res. 16:1996;3531-3536.
30. F. Meerson, T. Minko, V. Pozharov, E. Vorontsova, E. Ustinova, Effect of combined adaptation to stress and intermittent hypoxia on the development of experimental myocardial infarction, in: B.K. Sharma et al. (Eds.), Adaptation Biology and Medicine, Vol. I, Narosa Publishing House, New Delhi, India, 1997, pp. 419-426.
31. F. Meerson, V. Pozharov, T. Minko, Role of heat shock proteins and phenomenon of adaptive stabilization of structures (PhASS) in the protection of DNA against ischemic and mutagenic damages. Physiotherapeutic induction of PhASS, in: Proceedings of the 5th Congress of the International Society for Adaptive Medicine, Boston, MA, 7-19 September 1997, p. 2.
32. Meerson F., Pozharov V., Minyailenko T. Superresistance against hypoxia after preliminary adaptation to repeated stress. J. Appl. Physiol. 76:1994;1856-1861.
33. A.L. Lehninger, Biochemistry, 2nd ed., Worth Publishers, New York, 1976.
34. Tew D.T. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:1994;4313-4320.
35. Zaman G.J.R., Lankelma J., van Tellingen O., Beijnen J., Dekker H., Paulusma C., Oude R., Elfering P.J., Baas F., Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA. 92:1995;7690-7694.
36. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 31:1992;205-213.
37. Ferrand V.L., Chauvet M.M., Dell'Amico M.H., Tsuruo T., Hirn M.H., Bourdeaux M.J. MDR-related properties of K 562 cells grown in two different culture media. Anticancer Res. 16:1996;3653-3658.
38. Martell R.L., Slapac C.A., Levy S.B. Effect of glucose transport inhibitors on vincristine efflux in multidrug-resistant murine erythroleukaemia cells overexpressing the multidrug resistance-associated protein (MRP) and two glucose transport proteins, GLUT1 and GLUT3. Br. J. Cancer. 75:1997;161-168.
39. Chaudhary P.M., Roninson I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85:1997;632-639.
40. Putnam D.A., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
41. Cavalieri F. Drugs that target gene expression: an overview. Crit. Rev. Eukaryotic Gene Expr. 6:1996;75-85.
42. Euguchy E., Shimuzu S., Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. 57:1997;1835-1840.
43. Siesjo B.K., Katsura K.I., Kristian T., Li P.-A., Siesjo P. Molecular mechanisms of acidosis-mediated damage. Acta Neurochir. 66(Suppl.):1996;8-14.